Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease (COPD-LT)
Chronic Obstructive Pulmonary Disease (COPD)
About this trial
This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease (COPD) focused on measuring Flow-Mediated Dilation, Kuvan, Antioxidant, FEV1
Eligibility Criteria
Inclusion Criteria:
- patients with medically diagnosed COPD
- apparently healthy controls
Exclusion Criteria:
- FEV1/FVC >0.7 (normal lung function in patients only)
- Clinical diagnosis of heart disease or diabetes
- Vasoactive medications (i.e. nitrates, beta-blockers, Viagra etc.)
- uncontrolled high blood pressure
- high blood pressure in your lungs
- thyroid problems
- Fluid in the lungs
- Sleep apnea
- Anemia
- Raynaud's Phenomenon
- GI bleeding
- Gangrene of the digits
- History of low platelets or coagulopathies
- Phenylketonuria (PKU)
- Any allergy to Kuvan
Sites / Locations
- Georgia Prevention Institute
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Tetrahydrobiopterin (BH4)
Antioxidant Cocktail
Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following 5mg/kg of Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), taken once a day.
Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day.